Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Owlstone Medical appoints five leading experts to Scientific Advisory Board

Owlstone Medical logo 9.3.18Owlstone Medical, a diagnostics company developing a breathalyser for disease, has appointed five leading experts in a range of disciplines to its Scientific Advisory Board as the company expands and drives towards its goal of saving 100,000 lives and saving health care providers $1.5 billion.

Owlstone Medical has been advised by Professor Sir Bruce Ponder, Emeritus Professor of Oncology at the University of Cambridge, since June 2017, supporting the application of the company’s Breath Biopsy® platform to solve challenging questions in oncology, in particular in screening for the early detection of cancer, which is when treatment can be most effective.

Professor Ponder is now being joined by leading experts in areas critical to the development of the business: oncology, personalised medicine, breath testing, biomarker discovery, mass spectrometry, and toxicology and pharmacology. Owlstone Medical’s SAB will provide support and guide the company on product development, technology platform evolution and clinical programme design during its next phase of growth.

The new appointees are:

Dr Patrick Bossuyt, Professor of Clinical Epidemiology at the University of Amsterdam and Chair of the Division of Public Health & Clinical Methods in the Academic Medical Center. He leads the Biomarker and Test Evaluation Research programme in Amsterdam, which aims to appraise and develop methods for evaluating medical tests and biomarkers, and to apply these methods in relevant clinical studies.

Dr Christian Frezza, an MRC Programme Leader at the MRC Cancer Unit, University of Cambridge. His research is focused on understanding the role of altered metabolism in cancer, particularly in investigating how small-molecule metabolites affect the process of tumorigenesis, with the goal of exploiting this knowledge to pioneer novel tools for cancer diagnosis and therapy.

Dr Chris Mayhew, Director of the Institute for Breath Research at the University of Innsbruck and leader of the Molecular Physics Group at the school of Physics and Astronomy at the University of Birmingham. His research involves the use of soft chemical ionisation mass spectrometric techniques in the fields of health science, atmospheric chemistry and homeland security.

Dr Anil Modak, formerly Associate Director of Medical Products Research & Development at Cambridge Isotope Laboratories and an expert in stable isotope breath tests and consultant to life science and technology companies. He has been involved in the design, research and development of novel non-invasive breath tests for personalised medicine using stable isotope substrates for the monitoring of disease severity/toxicity and the evaluation of drug metabolising enzyme activity.

Dr Alan Boobis, Professor of Toxicology at Imperial College London. He retired from his position at the College as Professor of Biochemical Pharmacology and Director of the Public Health England/ Department of Health-supported Toxicology Unit in June 2017. His main research interests lie in mechanistic toxicology, drug metabolism, mode of action and chemical risk assessment.

Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “Owlstone Medical is in a period of rapid growth, with an increasing number of pharmaceutical companies partnering with us to identify novel breath biomarkers; several high-profile clinical trials underway in the areas of lung, colorectal, and other forms of cancer; and multiple products in development targeted to reach market in the next twelve months. Supported by recent financing activities, we are set to accelerate our development, and so have established a world-class advisory network to help guide us through our next phase of growth. The SAB forms a key strategic resource for the company and I am very pleased that we have been able to recruit such experienced and well-respected members to join us on our journey.”

For further information about Owlstone Medical visit www.owlstonemedical.com

Last modified onThursday, 09 August 2018 04:23